A carregar...
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells
Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olap...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6154848/ https://ncbi.nlm.nih.gov/pubmed/30024813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472189 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|